Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study - Archive ouverte HAL
Article Dans Une Revue The Lancet Haematology Année : 2021

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

Élie Azoulay (1) , Pedro Castro (2) , Adel Maamar (3, 4) , Victoria Metaxa (5) , Alice Gallo de Moraes (6) , Louis Voigt (7, 8) , Florent Wallet (9) , Kada Klouche (10, 11) , Muriel Picard (12) , Anne-Sophie Moreau (13) , Andry van de Louw (14) , Amélie Seguin (15) , Djamel Mokart (16) , Sanjay Chawla (7, 8) , Julien Leroy (1) , Boris Böll (17) , Nahema Issa (18) , Bruno Levy (19, 20) , Pleun Hemelaar (21) , Sara Fernandez (22) , Laveena Munshi (23) , Philippe Bauer (6) , Peter Schellongowski (24) , Michael Joannidis (25) , Gabriel Moreno-Gonzalez (2) , Gennadii Galstian , Michael Darmon (1) , Sandrine Valade (1) , Lara Zafrani , Eric Mariotte , Virginie Lemiale , Bertrand Arnulf , Nicolas Boissel , Catherine Thieblemont , Florence Rabian , Stéphanie Harel , Roberta Di Blasi , Julio Delgado , Valentin Ortiz , Didier Blaise , Sabine Fürst , Faezeh Legrand , Christian Chabannon (26) , Edouard Forcade , François-Xavier Gros , Cécile Borel , Anne Huynh , Christian Récher , Jakob Rudzki , Kevin Rakszawski , Pierre Sesques , Emmanuel Bachy , Gilles Salles , Miguel Perales , Philipp Wohlfarth , Thomas Staudingert , Ulrich Jäger , Guillaume Cartron (11, 27) , Nathalie Fégueux , Patrice Ceballos , Laura Platon , Thomas Gastinne , Benoit Tessoulin , Amandine Le Bourgeois , Olga Gavrilina , Anna Sureda , Alberto Mussetti , Jorge Garcia Borrega , Peter Borchmann , Yi Lin , Reuben Benjamin , Sophie de Guibert , Quentin Quelven , Ibrahim Yakoub-Agha (28) , David Beauvais , Marie-Therese Rubio
1 AP-HP - Hopital Saint-Louis [AP-HP]
2 University of Barcelona
3 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
4 CIC - Centre d'Investigation Clinique [Rennes]
5 KCH - King's College Hospital
6 Mayo Clinic [Rochester]
7 Memorial Sloane Kettering Cancer Center [New York]
8 Weill Medical College of Cornell University [New York]
9 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
10 PhyMedExp - Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046]
11 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
12 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
13 Hôpital Roger Salengro [Lille]
14 Penn State Health Milton S. Hershey Medical Center
15 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
16 IPC - Institut Paoli-Calmettes
17 Uniklinik Köln - Universitätsklinikum Köln
18 Hôpital Saint-André [Bordeaux]
19 DCAC - Défaillance Cardiovasculaire Aiguë et Chronique
20 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
21 Radboud University Medical Center [Nijmegen]
22 UB - Universitat de Barcelona
23 University of Toronto
24 Medizinische Universität Wien = Medical University of Vienna
25 Leopold Franzens Universität Innsbruck - University of Innsbruck
26 CRCM - Centre de Recherche en Cancérologie de Marseille
27 IGMM - Institut de Génétique Moléculaire de Montpellier
28 INFINITE - Institute for Translational Research in Inflammation - U 1286
Élie Azoulay
Connectez-vous pour contacter l'auteur
Florent Wallet
Anne-Sophie Moreau
Philippe Bauer
  • Fonction : Auteur
  • PersonId : 787114
  • IdRef : 156306042
Gennadii Galstian
  • Fonction : Auteur
Michael Darmon
Sandrine Valade
Lara Zafrani
  • Fonction : Auteur
Eric Mariotte
  • Fonction : Auteur
Virginie Lemiale
  • Fonction : Auteur
Bertrand Arnulf
  • Fonction : Auteur
Nicolas Boissel
  • Fonction : Auteur
Catherine Thieblemont
  • Fonction : Auteur
Florence Rabian
  • Fonction : Auteur
Stéphanie Harel
  • Fonction : Auteur
Roberta Di Blasi
Julio Delgado
  • Fonction : Auteur
Valentin Ortiz
  • Fonction : Auteur
Didier Blaise
Sabine Fürst
  • Fonction : Auteur
Faezeh Legrand
  • Fonction : Auteur
Edouard Forcade
François-Xavier Gros
  • Fonction : Auteur
Cécile Borel
  • Fonction : Auteur
Anne Huynh
  • Fonction : Auteur
Christian Récher
Jakob Rudzki
  • Fonction : Auteur
Kevin Rakszawski
  • Fonction : Auteur
Pierre Sesques
Emmanuel Bachy
Gilles Salles
Miguel Perales
  • Fonction : Auteur
Philipp Wohlfarth
  • Fonction : Auteur
Thomas Staudingert
  • Fonction : Auteur
Ulrich Jäger
  • Fonction : Auteur
Nathalie Fégueux
  • Fonction : Auteur
Patrice Ceballos
  • Fonction : Auteur
Laura Platon
  • Fonction : Auteur
Thomas Gastinne
  • Fonction : Auteur
Benoit Tessoulin
Amandine Le Bourgeois
  • Fonction : Auteur
Olga Gavrilina
  • Fonction : Auteur
Anna Sureda
  • Fonction : Auteur
Alberto Mussetti
  • Fonction : Auteur
Jorge Garcia Borrega
  • Fonction : Auteur
Peter Borchmann
  • Fonction : Auteur
Yi Lin
  • Fonction : Auteur
Reuben Benjamin
  • Fonction : Auteur
Sophie de Guibert
  • Fonction : Auteur
Quentin Quelven
  • Fonction : Auteur
David Beauvais
Marie-Therese Rubio

Résumé

Background: Chimeric antigen receptor (CAR) T-cell therapy can induce side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), which often require intensive care unit admission. The aim of this study was to describe management of critically ill CAR T-cell recipients in intensive care.Methods: This international, multicentre, observational cohort study was done in 21 intensive care units in France, Spain, the USA, the UK, Russia, Canada, Germany, and Austria. Eligible patients were aged 18 years or older; had received CAR T-cell therapy in the past 30 days; and had been admitted to intensive care for any reason. Investigators retrospectively included patients admitted between Feb 1, 2018, and Feb 1, 2019, and prospectively included patients admitted between March 1, 2019, and Feb 1, 2020. Demographic, clinical, laboratory, treatment, and outcome data were extracted from medical records. The primary endpoint was 90-day mortality. Factors associated with mortality were identified using a Cox proportional hazard model.Findings: 942 patients received CAR T-cell therapy, of whom 258 (27%) required admission to intensive care and 241 (26%) were included in the analysis. Admission to intensive care was needed within median 4·5 days (IQR 2·0-7·0) of CAR T-cell infusion. 90-day mortality was 22·4% (95% CI 17·1-27·7; 54 deaths). At initial evaluation on admission, isolated cytokine release syndrome was identified in 101 patients (42%), cytokine release syndrome and ICANS in 93 (39%), and isolated ICANS in seven (3%) patients. Grade 3-4 cytokine release syndrome within 1 day of admission to intensive care was found in 50 (25%) of 200 patients and grade 3-4 ICANS in 38 (35%) of 108 patients. Bacterial infection developed in 30 (12%) patients. Life-saving treatments were used in 75 (31%) patients within 24 h of admission to intensive care, primarily vasoactive drugs in 65 (27%) patients. Factors independently associated with 90-day mortality by multivariable analysis were frailty (hazard ratio 2·51 [95% CI 1·37-4·57]), bacterial infection (2·12 [1·11-4·08]), and lifesaving therapy within 24 h of admission (1·80 [1·05-3·10]).Interpretation: Critical care management is an integral part of CAR T-cell therapy and should be standardised. Studies to improve infection prevention and treatment in these high-risk patients are warranted.

Domaines

Hématologie
Fichier principal
Vignette du fichier
2021 Azoulay et al., Outcomes in patients.pdf (34.79 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03208127 , version 1 (12-06-2021)

Identifiants

Citer

Élie Azoulay, Pedro Castro, Adel Maamar, Victoria Metaxa, Alice Gallo de Moraes, et al.. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. The Lancet Haematology, 2021, 8 (5), pp.e355-e364. ⟨10.1016/S2352-3026(21)00060-0⟩. ⟨hal-03208127⟩
1096 Consultations
366 Téléchargements

Altmetric

Partager

More